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Large-scale, genome-wide sequencing efforts have compre-
hensively characterized genomic and transcriptomic land-
scape of prostate cancer, revealing recurrently altered genes
as well as substantial heterogeneity in cancer-driving muta-
tions. Recently, integrative proteogenomic studies of prostate
tumor samples have demonstrated that, in fact, there is a poor
correlation between alterations in the genome and tran-
scriptome compared with the proteomic profiles, suggesting
that a large fraction of the accrued changes at nucleotide
levels are insignificant with respect to protein functions. The
proteomic profiling has provided an enhanced view of
deregulated pathways during development of prostate cancer
and formation of castration resistance. These results underline
the importance of proteogenomic analyses to gain better un-
derstanding of the cancer phenotypes and to develop more
effective therapeutic strategies.
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Prostate cancer is the second most commonly diagnosed
cancer among males worldwide and the most frequently
diagnosed malignancy in developed countries [1]. The
number of prostate cancer cases has increased by 42%
during the last decade [2]. The disease often progresses
slowly, and surgical removal of the tumor by radical
prostatectomy or radiation therapy are effective treat-
ments for organ-confined prostate cancer. Cancers that
have spread outside the prostatic capsule are treated
hormonally, either by surgical or chemical castration or
by antiandrogens. Although initially effective, hormonal
therapy eventually fails in over 80% of the cases, and the
cancer becomes hormone-refractory, that is, resistant to
therapy (castration-resistant prostate cancer; CRPC)
[3]. Currently, there is no effective treatment for CRPC.
In addition, there is a lack of reliable markers to identify
more aggressive forms of the disease at the time of
diagnosis. A recent development in the treatment of
advanced disease has sprung from the use of next gen-
eration antiandrogen drugs, such as abiraterone and
enzalutamide. However, although effective at slowing
down disease progression [4,5], these drugs are
responsible for an increase in treatment-induced
neuroendocrine (NE) type cases, characterized by a
highly aggressive phenotype [6,7].
During the last decade, next-generation sequencing
technologies have revolutionized studies of human ge-
netics and diseases, including cancer. Several genome-
wide analyses of genetic and transcriptional changes
have been performed in prostate cancer with the aim of
finding the molecular alterations responsible for the
development and progression of this disease. These
studies led to the identification of several, recurrent
deletions and mutations in tumor-suppressor genes,
amplifications of oncogenic loci, aberrations in genes
involved in key cellular pathways such as androgen re-
ceptor (AR) signaling, novel noncoding RNA species, as
well as common chromatin rearrangements [8e14].
Moreover, recent efforts by The Cancer Genome
Atlas and the Prostate Cancer Foundation/Stand Up to
Cancer (PCF/SU2C) consortia, using significantly larger
cohorts of clinical samples, allowed the characterization
of additional recurrent mutations at lower frequencies.
These efforts revealed a substantial heterogeneity of
alterations in prostate cancer, as well as a long-tail dis-
tribution in the incidence of mutated oncogenic driversrrent Opinion in Endocrine and Metabolic Research 2020, 10:43–49
44 Prostate cancer[15,16]. Despite this uncovered complexity of alter-
ations at the genetic, epigenetic, and transcriptomic
levels, only recently have we started to discover how
these affect the proteomic landscape of prostate cancer
(Figure 1).
Highly informative large-scale proteomics analyses (in
the order of thousands of quantitated proteins) have
been published from primary prostate tumors as well as
bone metastases [17e19]. These studies serve as valu-
able snapshots to the clinical proteome and provide in-
sights into the heterogeneity of the disease at the protein
level. Interestingly, recent reports have demonstrated a
poor correlation between expression changes at the
transcriptomic and proteomic levels in several types of
cancer [20e22]. These findings have highlighted the
need for studies that investigate the inference from
genomic abnormalities to cancer phenotypes by inte-
grative proteogenomic studies, as well as strategies to
improve the current methods for the identification and
characterization of aberrant protein products [23].Figure 1
Computational biology lens uncovers deeper insights into prostate canc
Samples collected from prostate cancer tissues are subjected to several types
of molecular alterations. Each level of data (left panel) by itself only explains
different computational biology methods (right panel), we can determine the e
proteome level, which represents the endpoint in the central dogma. Measure
translocations), epigenome (e.g. DNA methylation, histone modifications), tra
patterns, including posttranslational modifications) are represented. Other dat
accessibility data, could also be utilized to gain even deeper insights. These in
for the disease. TAD, topologically associated domain.
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The first integrative study combining genomic and
transcriptomic analyses to full proteome from the same
clinical prostate tumor samples was published by Lato-
nen et al., in 2018 [24]. This study compared alterations
in primary prostate cancer and CRPC and, thus,
revealed alterations occurring during the development
of the disease as well as during the formation of treat-
ment resistance. In the study, a cohort of clinical sam-
ples including benign prostatic hyperplasia, untreated
primary tumors, and locally recurrent CRPC cases were
analyzed with mass spectrometry (MS) and SWATH-
quantitation-based proteomics. The high-confidence
data of 3400 proteins were integrated with previously
generated genetic, epigenetic, and transcriptomic pro-
files of the same samples [13,14]. The results of these
analyses showed that, especially in CRPC, gene copy
number, DNA methylation, and RNA expression levels
do not reliably predict proteomic changes. Differentially
expressed proteins and novel regulated pathways thater by integrating multiple levels of data along the central dogma.
of high throughput measurements providing different information and views
parts of what is observed in the proteome. Integrating these data using
xtent to which changes at one level contribute to what is observed at the
ments of alterations in the genome (e.g. SNVs, insertions, deletions, and
nscriptome (RNA expression patterns), and proteome (protein expression
a modalities, such as protein-DNA interactions as well as chromatin
sights aid in devising better biomarkers and enhanced future therapeutics
www.sciencedirect.com
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mRNA level were identified in both primary and more
advanced stages of the disease. Moreover, several novel
miRNA-target gene interactions were found to affect
the protein endproduct with no significant changes at
mRNA level, providing miRNA targets to further assess
for potential clinical applications. Overall, this study
provided valuable new insight into proteomic changes
throughout the development and progression of the
disease and into potential use of proteomic data to
develop new therapeutic strategies.
The second integrative large-scale proteomics study
from prostate cancer was performed on a clinically ho-
mogeneous cohort of localized, treatment-naı¨ve primary
prostate tumors analyzed with MS shotgun proteomics
[25]. Approximately 3400 individual proteins were
identified in all samples. Integrative analysis of genome,
methylome, and transcriptome showed that genomic and
proteomic features are poorly correlated, confirming
previous observations in prostate cancer [24] and other
cancer types [20e22]. In this study, gene fusions of the
erythroblast transformation-specific (ETS) gene family,
which are the most frequently occurring somatic aber-
rations in prostate cancer and not associated with clinical
outcome, were found to be significantly associated with
changes in protein abundances. The proteins that were
most affected by the presence of ETS fusion showed a
good correlation with their mRNA level. However, many
genes associated with ETS fusion status either at mRNA
or protein level only. In this article, five subtypes of pri-
mary prostate cancer were identified based on the pro-
teome. Surprisingly, genomic and proteomic subtypes
were largely independent, as were proteomic subtypes of
mutational burden [genomic rearrangements (GRs) and
single nucleotide variants (SNVs)] and AR activity
signaturesdas expected for treatment-naı¨ve cases [25].Poor correlation of genomic and
epigenomic events with the prostate cancer
proteome
Both of the current integrative proteogenomic studies of
prostate cancer show that genomic and proteomic fea-
tures are poorly correlated [24,25]. Primary prostate
cancer is driven by copy number alterations (CNVs)more
than SNVs [26], yet, only 2% of proteins have their
abundance associated with CNAs [25]. Furthermore, the
mutational burden as a whole (genomic rearrangements
and SNVs) in primary prostate cancer patients was not
significantly associated with tumor protein abundance
profile [25]. Latonen et al. (2018) showed that neither
the altered gene copy numbers nor the global methyl-
ation changes were detectable through the proteome to
the same extent as they correlate with the global RNA
expression. This was especially prominent in CRPC,
where significantly more genomic aberrations exist
compared with primary cancers [24]. This indicates thatwww.sciencedirect.com Cua large proportion of genomic aberrations that accrue to
the tumors are untranslated and subsequently left
without a functional effect at the protein level.The transcriptome is a poor predictor of the
proteome in prostate cancer
Globally, mRNA and protein abundances are only weakly
correlated in primary prostate cancers [24,25], and this
correlation is further decreased in CRPC [24]. Some
genes even show opposite expression patterns at mRNA
compared with protein levels, and mRNA abundance
explains only around 10% of protein abundance vari-
ability in primary prostate cancer [24,25]. E.g. deletion
of PTEN affects abundance of around half of the stud-
ied genes at the mRNA level, but only 2.7% at the
protein level [25]. Similar findings have been reported
for breast, ovarian, and colorectal cancer [20,22], indi-
cating that the transcriptome is a poor predictor of the
proteome in cancer. Nevertheless, the transcriptomic
changes observed are likely to affect cellular functions
that are dependent on noncoding RNAs and possible
translation-independent functions of mRNA.
Interestingly, 10% ofmost abundant proteins were better
correlated with their respective mRNAs than the 10%
least abundant proteins detected in the primary prostate
cancer proteomes [25]. This finding likely reflects the
differential role and regulation of these protein groups.
While the high abundance proteins that are more easily
detected by MS approaches often represent structural
and core function proteins (e.g. membrane-bound or-
ganelles, extracellular proteins, cytoskeletal and attach-
ment proteins, ribosomal proteins of protein synthesis),
many highly and transiently regulated proteins such as
signal transductors and transcription factors are generally
lower in abundance. This is supported by the notion that
an overrepresentation of nuclear proteins was found in
genes with coding transcripts expressed but no protein
detected [25]. Conversely, an overrepresentation of
immune-related genes was found for proteins with no
mRNA detected [25], suggesting that the source of gene
expression lies elsewhere than in the tumor cells.Integrative proteomics view of prostate
cancer pathways
In addition to characterization of the overall protein
levels, the integrative analyses have also provided views
to explain how alterations in protein levels and post-
translational regulation affect cellular functions
(Figure 2). A valuable study in this direction was
presented by Drake et al. (2016) [27], who compared
genomic, transcriptomic, and phosphoproteomic (anti-
body-based extraction of pST- and pY-containing pep-
tides) data sets from metastatic CRPC samples.
Differentially expressed master transcriptional regula-
tors, functionally mutated genes, and differentially
activated kinases were revealed indicating 6 majorrrent Opinion in Endocrine and Metabolic Research 2020, 10:43–49
Figure 2
Summary of proteomics-based view of altered functional pathways in prostate cancer. While alterations in protein metabolism, GTPase signaling
and vesicular traffic are emphasized in primary cancer, and cell cycle, nuclear receptor, and stemness pathway alterations in castration-resistant prostate
cancer, both stages involve DNA repair, metabolism, and PI3K/AKT/mTOR pathway alterations that are detectable at the protein level. Especially
considering how poor predictor the transcriptome is for the proteome in prostate cancer (see main text for details), these pathway alterations identified
based on large scale proteomics are promising candidates for cancer targeting. For treatment-induced NE tumors, large-scale proteomics and integrative
proteogenomic profiling is yet to be performed. The most relevant references used to form this view were [17,18,24,25,27]. Background image by Florian
H. Tirk (Tirkfl) - No machine-readable source provided. Own work assumed (based on copyright claims). CC BY-SA 3.0, https://commons.wikimedia.org/
w/index.php?curid=1417737.
46 Prostate cancersignaling pathways with phosphorylation of several key
residues. These included cell cycle, DNA repair, nuclear
receptor, PI3K-AKT-mTOR, stemness (including
TGFb, WNT, NOTCH, and MYC pathways), and
migration and invasion pathways [27].
When comparing altered pathways based on RNA and
protein expression data, Latonen et al. (2018) [24]
showed that less than a third of them were common.
Interestingly, even though cell metabolism is already
well known to undergo alterations in cancer, the inte-
grative proteomics studies revealed novel information to
this aspect. In primary cancer, ERG-fusions were found
to associate with carboxylic acid metabolism, corrobo-
rating the links between ERG and lipid metabolism
[25]. In Latonen et al., sequential changes in the citric
acid cycle (Krebs cycle) were identified first during
cancer development and then during formation of
treatment resistance. Metabolic pathway alterations
were not identified by phosphoproteomic analyses,
likely reflecting the fact that metabolic enzymes, as
many other housekeeping proteins, are subject to less
posttranslational regulation than, for example, signaling
proteins. Conversely, DNA repair, migration-related and
invasion-related, as well as PI3K-AKT-mTOR pathways
were all detected by both proteomic and phosphopro-
teomic analyses [24,26].
In primary cancer, ETS fusions overall were associated
with alterations in pathways governing intracellular andCurrent Opinion in Endocrine and Metabolic Research 2020, 10:43–49extracellular vesicles and lysosomal genes [25]. Also,
translation-related and protein degradation-related
pathways as well as GTPase signaling were picked by
proteomics better than transcriptomics [17,24]. The
notion that proteomic data can reveal pathway alter-
ations not visible through RNA expression was espe-
cially true in CRPC, where alterations in DNA
metabolism and repair, cell metabolism, and various
signaling events were better spotted [18,24]. Further,
the poor correlation of protein levels with mRNA
expression in CRPC was reflected through the fact that
based on mRNA levels, several pathways were identified
to be altered which did not appear so based on the
protein levels. These divergences in altered, cancer-
associated signaling pathways detected by tran-
scriptomics and proteomics [24,25] underline that
caution should be taken in interpreting cellular activity
patterns and the effects of genomic aberrations by
transcriptomic data alone.Technical considerations and future
perspectives
With current technologies, large-scale proteomes are
still biased toward high-abundance proteins. This re-
sults in, for example, cytoplasmic and structural proteins
being overrepresented compared with low abundance
nuclear proteins and signaling proteins. Biologically, the
latter likely bear a high relevance in cancer development
and evolution. For these proteins, the post-
transcriptional activity regulation patterns are often alsowww.sciencedirect.com
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understanding of the prostate cancer proteomes. The
National Cancer Institute’s Clinical Proteomic Tumor
Analysis Consortium (https://proteomics.cancer.gov/
programs/cptac) represents a major effort aiming at
better understanding the molecular basis of cancer
through the collection of large scale glycoproteomes and
phosphoproteomes in addition to full proteomes from
several cancer types, including prostate cancer. Further,
the development of high-throughput single cell prote-
omics approaches will be essential to dissect tumor cell
heterogeneity at the protein level.
Another major challenge for the future is assessing the
functional subproteomes in prostate cancer, such as the
interactomes of key cancer driving factors. Several
studies performed in cell lines report wildtype and
prostate cancer-related T877A mutant AR interactomes
based on affinity purification or proximity labeling
followed by MS [28e32]. Another relevant subpro-
teome studied in cell lines is the N-Myc-interactome,
shedding light on events taking place in NE-type CRPC
[33]. While most of these studies correlate their findings
with chromatin binding and/or gene expression results,
genuine integrative views of activation and mutation
status-dependent changes in the relevant transcription
factor interactomes are lacking both in cell line models
as well as in prostate cancer tumors. Further, the treat-
ment resistance linked to NE development of prostate
tumors treated with next generation antiandrogens has
so far been explored at the proteomic level only in
patient-derived xenografts [34]. The integrative
proteogenomic profiling of treatment-induced NE
tumors is one key task for future studies (Figure 2),
especially for understanding tumor cell plasticity not
evidenced at the genetic level, which plays a central role
in treatment resistance.Final words
It has already been shown that prognostic biomarkers
based on integrating multiomics significantly outper-
form those based on a single data type [25]. Beyond
biomarkers, discoveries for better treatments in the
future require a comprehensive understanding of pros-
tate cancer biology at all molecular levels. After the leap
that the current proteogenomic studies have provided
us, knowledge and integration of functional subpro-
teomes and metabolomes are warranted for further steps
toward curative prostate cancer therapies also for the
advanced disease.Conflict of interest statement
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